End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | -1.48% | -1.48% | -9.91% |
Valuation
Fiscal Period: June | 2022 | 2023 |
---|---|---|
Capitalization 1 | - | - |
Enterprise Value (EV) 1 | - | - |
P/E ratio | - | -1.24 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | - |
EV / FCF | - | - |
FCF Yield | - | - |
Price to Book | -1.69 x | -3.75 x |
Nbr of stocks (in thousands) | - | - |
Reference price 2 | 10.00 | 10.84 |
Announcement Date | 19/12/22 | 11/10/23 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | - |
EBIT 1 | -0.7337 | -1.685 | -11.11 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -0.7337 | -1.685 | -11.11 |
Net income 1 | -0.7337 | -1.685 | -11.11 |
Net margin | - | - | - |
EPS | - | - | -8.751 |
Free Cash Flow | - | - | 2.813 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 19/12/22 | 19/12/22 | 11/10/23 |
Balance Sheet Analysis
Fiscal Period: June | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt | - | - | - |
Net Cash position | - | 4.09 | 2.46 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | - | 2.81 |
ROE (net income / shareholders' equity) | - | - | 799% |
ROA (Net income/ Total Assets) | - | - | -175% |
Assets 1 | - | - | 6.36 |
Book Value Per Share | - | -5.910 | -2.890 |
Cash Flow per Share | - | 23.20 | 0.6100 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 19/12/22 | 19/12/22 | 11/10/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-9.91% | 3.66Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.39TCr | |
-1.69% | 2.16TCr | |
-10.60% | 1.9TCr | |
-41.25% | 1.7TCr | |
-15.33% | 1.63TCr | |
+5.80% | 1.41TCr | |
+28.03% | 1.2TCr |
- Stock Market
- Equities
- ESLA Stock
- Financials Estrella Immunopharma, Inc.